India's Weight-Loss Drug Revolution: A Global Perspective

Wed Mar 18 2026 20:24:17 GMT+0000 (Coordinated Universal Time)

The expiration of the patent on semaglutide in India signals a new era in the fight against obesity, potentially lowering costs and increasing access to weight-loss medications. This article explores the implications from various viewpoints, including medical, economic, and regulatory perspectives.

The expiration of semaglutide's patent in India could lead to a surge in affordable weight-loss medications, impacting both local health and the global market. With estimates suggesting the potential for a new $1 billion industry, Indian pharmaceutical firms stand ready to produce generics that could significantly lower treatment costs. However, concerns remain about drug quality and misuse, emphasizing the need for strict regulation as the market expands.

India could soon get a lot thinner - at least in theory. On Friday, the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country.

This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too. Investment bank Jefferies has called it a potential magic-pill moment for India, predicting the semaglutide market could eventually reach $1 billion domestically with the right pricing and uptake.

Analysts expect around 50 branded semaglutide generics to enter the market within months - a familiar pattern in India's fiercely competitive pharmaceutical industry. When the diabetes drug sitagliptin went off patent in 2022, about 30 branded versions appeared within a month and nearly 100 within a year.

India's pharmaceutical industry, currently worth about $60 billion, is expected to double by 2030, much of it built on generics - a manufacturing muscle that now sets the stage for fierce competition over semaglutide. What曾 past been an expensive injection largely confined to affluent patients could soon become far more common.

Originally developed to treat diabetes, semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar. By boosting insulin release and slowing the emptying of the stomach, these drugs make people feel full sooner and maintain satiety longer. They have become some of the most sought-after weight-loss treatments in the world.

Several Indian drugmakers are already preparing to compete in this burgeoning market, including major companies such as Cipla, Sun Pharma, and Dr. Reddy's Laboratories. Current monthly treatment costs are steep, with Ozempic selling for ₹8,800–11,000 and Wegovy ranging from ₹10,000–16,000. However, generic competition may drive these prices down to around ₹3,000–5,000 per month. This reduction could significantly transform the market for anti-obesity drugs, which has already grown rapidly, from roughly $16 million in 2021 to nearly $100 million.

Nonetheless, the rush to accessibility comes with challenges. There are concerns about the quality of the drugs, with caution urged by physicians regarding potential misuse as prices fall. Cases of patients being prescribed high doses by unauthorized personnel and the proliferation of online pharmacies dispensing these drugs hastily raise red flags.

As the market for GLP-1 drugs evolves, India's government is working to ensure that regulations keep pace with affordability. The push for accessibility must be balanced with the need for responsible oversight to prevent exploitation while ensuring the efficacy and safety of these vital medications.

As the world watches, India might not just be reshaping its health landscape but could lead a significant transformation in global health initiatives against obesity.